Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group

Shinkyo Yoon; Miso Kim; Yong Sang Hong; Han Sang Kim; Seung Tae Kim; Jihun Kim; Hongseok Yun; Changhoon Yoo; Hee Kyung Ahn; Hyo Song Kim; In Hee Lee; In Ho Kim; Inkeun Park; Jae Ho Jeong; Jaekyung Cheon; Jin Won Kim; Jina Yun; Sun Min Lim; Yongjun Cha; Se Jin Jang; Dae Young Zang; Tae Won Kim; Jin Hyoung Kang; Jee Hyun Kim

doi:10.4143/CRT.2021.1115

Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group

Shinkyo Yoon, Miso Kim, Yong Sang Hong, Han Sang Kim, Seung Tae Kim, Jihun Kim, Hongseok Yun, Changhoon Yoo, Hee Kyung Ahn, Hyo Song Kim, In Hee Lee, In Ho Kim, Inkeun Park, Jae Ho Jeong, Jaekyung Cheon, Jin Won Kim, Jina Yun, Sun Min Lim, Yongjun Cha, Se Jin JangDae Young Zang, Tae Won Kim, Jin Hyoung Kang, Jee Hyun Kim

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumor board (MTB) is multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. Although guidelines for NGS use and MTB have been developed in western countries, there is limitation for reflection of Korea’s public health environment and daily clinical practice. These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.

Original language	English
Pages (from-to)	1-9
Number of pages	9
Journal	Cancer Research and Treatment
Volume	54
Issue number	1
DOIs	https://doi.org/10.4143/CRT.2021.1115
Publication status	Published - 2022 Jan

Bibliographical note

Funding Information:
This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1720150).

Publisher Copyright:
Copyright © 2022 by the Korean Cancer Association.

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4143/CRT.2021.1115

Cite this

Yoon, S., Kim, M., Hong, Y. S., Kim, H. S., Kim, S. T., Kim, J., Yun, H., Yoo, C., Ahn, H. K., Kim, H. S., Lee, I. H., Kim, I. H., Park, I., Jeong, J. H., Cheon, J., Kim, J. W., Yun, J., Lim, S. M., Cha, Y., ... Kim, J. H. (2022). Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group. Cancer Research and Treatment, 54(1), 1-9. https://doi.org/10.4143/CRT.2021.1115

@article{9f2fe0f690d04706828625fa2b535b0c,

title = "Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group",

abstract = "Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumor board (MTB) is multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. Although guidelines for NGS use and MTB have been developed in western countries, there is limitation for reflection of Korea{\textquoteright}s public health environment and daily clinical practice. These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.",

author = "Shinkyo Yoon and Miso Kim and Hong, {Yong Sang} and Kim, {Han Sang} and Kim, {Seung Tae} and Jihun Kim and Hongseok Yun and Changhoon Yoo and Ahn, {Hee Kyung} and Kim, {Hyo Song} and Lee, {In Hee} and Kim, {In Ho} and Inkeun Park and Jeong, {Jae Ho} and Jaekyung Cheon and Kim, {Jin Won} and Jina Yun and Lim, {Sun Min} and Yongjun Cha and Jang, {Se Jin} and Zang, {Dae Young} and Kim, {Tae Won} and Kang, {Jin Hyoung} and Kim, {Jee Hyun}",

note = "Funding Information: This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1720150). Publisher Copyright: Copyright {\textcopyright} 2022 by the Korean Cancer Association.",

year = "2022",

month = jan,

doi = "10.4143/CRT.2021.1115",

language = "English",

volume = "54",

pages = "1--9",

journal = "Cancer Research and Treatment",

issn = "1598-2998",

publisher = "Korean Cancer Association",

number = "1",

}

Yoon, S, Kim, M, Hong, YS, Kim, HS, Kim, ST, Kim, J, Yun, H, Yoo, C, Ahn, HK, Kim, HS, Lee, IH, Kim, IH, Park, I, Jeong, JH, Cheon, J, Kim, JW, Yun, J, Lim, SM, Cha, Y, Jang, SJ, Zang, DY, Kim, TW, Kang, JH & Kim, JH 2022, 'Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group', Cancer Research and Treatment, vol. 54, no. 1, pp. 1-9. https://doi.org/10.4143/CRT.2021.1115

Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group. / Yoon, Shinkyo; Kim, Miso; Hong, Yong Sang et al.
In: Cancer Research and Treatment, Vol. 54, No. 1, 01.2022, p. 1-9.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer

T2 - A Report from KSMO and KCSG Precision Medicine Networking Group

AU - Yoon, Shinkyo

AU - Kim, Miso

AU - Hong, Yong Sang

AU - Kim, Han Sang

AU - Kim, Seung Tae

AU - Kim, Jihun

AU - Yun, Hongseok

AU - Yoo, Changhoon

AU - Ahn, Hee Kyung

AU - Kim, Hyo Song

AU - Lee, In Hee

AU - Kim, In Ho

AU - Park, Inkeun

AU - Jeong, Jae Ho

AU - Cheon, Jaekyung

AU - Kim, Jin Won

AU - Yun, Jina

AU - Lim, Sun Min

AU - Cha, Yongjun

AU - Jang, Se Jin

AU - Zang, Dae Young

AU - Kim, Tae Won

AU - Kang, Jin Hyoung

AU - Kim, Jee Hyun

N1 - Funding Information: This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1720150). Publisher Copyright: Copyright © 2022 by the Korean Cancer Association.

PY - 2022/1

Y1 - 2022/1

N2 - Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumor board (MTB) is multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. Although guidelines for NGS use and MTB have been developed in western countries, there is limitation for reflection of Korea’s public health environment and daily clinical practice. These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.

AB - Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumor board (MTB) is multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. Although guidelines for NGS use and MTB have been developed in western countries, there is limitation for reflection of Korea’s public health environment and daily clinical practice. These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.

UR - http://www.scopus.com/inward/record.url?scp=85123602472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123602472&partnerID=8YFLogxK

U2 - 10.4143/CRT.2021.1115

DO - 10.4143/CRT.2021.1115

M3 - Article

C2 - 34902959

AN - SCOPUS:85123602472

SN - 1598-2998

VL - 54

SP - 1

EP - 9

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

IS - 1

ER -

Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this